Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F R Robertson

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
Breast Cancer (Tokyo, Japan)|December 3, 2002
Current role of endocrine therapy in the management of breast cancerJohn F R Robertson
The Oncologist|August 4, 2007
Fulvestrant (Faslodex) -- how to make a good drug betterJohn F R Robertson
Cancer Treatment Reviews|November 16, 2004
Selective oestrogen receptor modulators/new antioestrogens: a clinical perspectiveJohn F R Robertson
Breast Cancer Research : BCR|December 25, 2009
Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitorsEleanor Gutteridge, John F R Robertson
Lancet (London, England)|June 13, 2021
COVID-19 vaccine efficacy data: solid enough to delay second dose?John F R Robertson, Herb F Sewell
Expert Opinion on Investigational Drugs|February 7, 2002
FulvestrantKwok Leung Cheung, John F R Robertson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2016
Reply to T. Reinert et alMatthew J Ellis, John F R Robertson
Breast Cancer Research : BCR|December 22, 2010
Controversies in Breast Cancer 2010. Session 6 introductionJohn F R Robertson, Per Eystein Lønning
The Annals of Pharmacotherapy|August 17, 2006
Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancerAman U Buzdar, John F R Robertson
Cancer Chemotherapy and Pharmacology|July 25, 2003
Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant ('Faslodex') in postmenopausal women with advanced breast cancerJohn F R Robertson, M P Harrison
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
Breast Cancer (Tokyo, Japan)|December 3, 2002
Current role of endocrine therapy in the management of breast cancerJohn F R Robertson
The Oncologist|August 4, 2007
Fulvestrant (Faslodex) -- how to make a good drug betterJohn F R Robertson
Cancer Treatment Reviews|November 16, 2004
Selective oestrogen receptor modulators/new antioestrogens: a clinical perspectiveJohn F R Robertson
Breast Cancer Research : BCR|December 25, 2009
Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitorsEleanor Gutteridge, John F R Robertson
Lancet (London, England)|June 13, 2021
COVID-19 vaccine efficacy data: solid enough to delay second dose?John F R Robertson, Herb F Sewell
Expert Opinion on Investigational Drugs|February 7, 2002
FulvestrantKwok Leung Cheung, John F R Robertson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2016
Reply to T. Reinert et alMatthew J Ellis, John F R Robertson
Breast Cancer Research : BCR|December 22, 2010
Controversies in Breast Cancer 2010. Session 6 introductionJohn F R Robertson, Per Eystein Lønning
The Annals of Pharmacotherapy|August 17, 2006
Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancerAman U Buzdar, John F R Robertson
Cancer Chemotherapy and Pharmacology|July 25, 2003
Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant ('Faslodex') in postmenopausal women with advanced breast cancerJohn F R Robertson, M P Harrison
Pageof 9